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Objectives. The aim of the present investigation was to redefine
the clinicopathologic profile of arrhythmogenic right ventricular
cardiomyopathy/dysplasia (ARVC), with special reference to dis-
ease progression and left ventricular (LV) involvement.
Background. Long-term follow-up data from clinical studies
indicate that ARVC is a progressive heart muscle disease that with
time may lead to more diffuse right ventricular (RV) involvement
and LV abnormalities and culminate in heart failure.
Methods. Forty-two patients (27 male, 15 female; 9 to 65 years
old, mean [6SD] age 29.6 6 18) from six collaborative medical
centers, with a pathologic diagnosis of ARVC at autopsy or heart
transplantation, and with the whole heart available, were studied
according to a specific clinicomorphologic protocol.
Results. Thirty-four patients died suddenly (16 during effort); 4
underwent heart transplantation; 2 died as a result of advanced
heart failure; and 2 died of other causes. Sudden death was the
first sign of disease in 12 patients; the other 30 had palpitations,
with syncope in 11, heart failure in 8 and stroke in 3. Twenty-seven
patients experienced ventricular arrhythmias (ventricular tachy-
cardia in 17), and 5 received a pacemaker. Ten patients had
isolated RV involvement (group A); the remaining 32 (76%) also
had fibrofatty LV involvement that was observed histologically
only in 15 (group B) and histologically and macroscopically in 17
(group C). Patients in group C were significantly older than those
in groups A and B (39 6 15 years vs. 20 6 8.8 and 25 6 9.7 years,
respectively), had significantly longer clinical follow-up (9.3 6 7.3
years vs. 1.2 6 2.1 and 3.4 6 2.2 years, respectively) and developed
heart failure significantly more often (47% vs. 0 and 0, respective-
ly). Patients in groups B and C had warning symptoms (80% and
87%, respectively, vs. 30%) and clinical ventricular arrhythmias
(73% and 82%, respectively, vs. 20%) significantly more often than
patients in group A. Hearts from patients in group C weighed
significantly more than those from patients in groups A and B
(500 6 150 g vs. 328 6 40 and 380 6 95 g, respectively), whereas
hearts from both group B and C patients had severe RV thinning
(87% and 71%, respectively, vs. 20%) and inflammatory infiltrates
(73% and 88%, respectively, vs. 30%) significantly more often than
those from group A patients.
Conclusions. LV involvement was found in 76% of hearts with
ARVC, was age dependent and was associated with clinical
arrhythmic events, more severe cardiomegaly, inflammatory infil-
trates and heart failure. ARVC can no longer be regarded as an
isolated disease of the right ventricle.
(J Am Coll Cardiol 1997;30:1512–20)
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Arrhythmogenic right ventricular cardiomyopathy/dysplasia
(ARVC) is a heart muscle disease that is characterized patho-
logically by right ventricular (RV) myocardial atrophy and
fibrofatty replacement (1–5). Previous reports (6–18) focused
mainly on the peculiar RV involvement and the electrical
instability precipitating ventricular tachycardia and sudden
death (6–18). Long-term follow-up data from clinical studies
indicate that ARVC is a progressive heart muscle disease that
with time may lead to more diffuse RV involvement and left
ventricular (LV) changes (19,20) and may culminate in heart
failure (21–24). In the advanced stage, ARVC may be difficult
to distinguish clinically from dilated cardiomyopathy.
The aim of the present multicenter investigation was to
redefine the anatomoclinic profile of ARVC, with special
reference to disease progression and involvement of the left
ventricle, by studying a number of affected whole hearts and
correlating pathologic findings with patient clinical history. To
include the complete spectrum of manifestations of ARVC, six
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collaborative medical centers with clinicopathologic experi-
ence in ARVC participated in the investigation.
Methods
The study group included 42 hearts of patients with a
pathologic diagnosis of ARVC at postmortem examination or
after heart transplantation. Only whole hearts available for
detailed morphologic investigation of both ventricles and the
septum were studied. Incomplete native hearts, partial surgical
resections or endomyocardial biopsy specimens, even though
morphologically consistent with ARVC, were ruled out. Hearts
were included in the study if they exhibited transmural loss of
RV musculature with fibrofatty replacement, either regional or
diffuse, in the absence of significant coronary artery disease or
other known causes and irrespective of the severity of coexis-
tent LV involvement.
The study was carried out in the setting of a cooperative
European investigation that included six collaborative medical
centers: University of Padua, Padua, Italy (19 cases); Univer-
sity of Trieste, Trieste, Italy (9 cases); Hoˆpital J. Rostand,
Paris, France (6 cases); St. George’s Hospital, University of
London, London, England, United Kingdom (6 cases); Uni-
versity of Uppsala, Uppsala, Sweden (1 case); University of
Warsaw, Warsaw, Poland (1 case). Clinical history and heart
morphology were evaluated according to a specific clinicopath-
ologic protocol developed by the Task Force of the Interna-
tional Society of the Federation of Cardiology. Data were
collected in a central registry and recorded in a data base for
computerized analysis.
Clinical data. Retrospective clinical information included
patient age and gender, family history of premature sudden
death (age ,40 years) or ARVC, symptoms at clinical presen-
tation and during follow-up, physical examination, 12-lead
electrocardiographic (ECG) changes, arrhythmias, echocar-
diographic and angiographic findings, drug therapy and cir-
cumstances and cause of death.
Sudden death was defined as an unexpected natural phe-
nomenon in which loss of all vital functions occurred instan-
taneously or within 1 h of the onset of symptoms or collapse.
Syncope was defined as a sudden transient loss of conscious-
ness not requiring electrical cardioversion for recovery. Ven-
tricular tachycardia was defined as sustained (.30 s) or non-
sustained (#30 s). The QRS configuration during spontaneous
ventricular tachycardia was classified according to the bundle
branch block and axis deviation pattern.
Pathologic data. Gross examination. All hearts were fixed
in formaline and examined by the local cardiovascular pathol-
ogist (G.T., M.J.D., F.S., F.F.). Macroscopic examination
included measurement of heart weight, chamber size and wall
thickness, as well as inspection of coronary arteries (origin,
course and patency) and valves. The following regions were
systematically examined: inflow tract, outflow tract, apex,
posterolateral and anterolateral walls of both ventricles and
the interventricular septum. The following morphologic
changes were addressed: 1) wall thinning; 2) cavity enlarge-
ment or aneurysms, or both; 3) myocardial atrophy and fatty
replacement; 4) fibrosis; 5) parietal thrombosis; and 6) endo-
cardial fibrosis. The changes were evaluated in terms of
severity (mild, moderate, severe), transmural extension (sub-
epicardial to full thickness) and distribution (monofocal, mul-
tifocal, diffuse). Extent and distribution of ventricular muscle
atrophy were confirmed by wall transillumination.
ARVC was defined as regional when it was limited to
certain RV regions. A transmural lesion was defined as one
that extended through the entire thickness of the ventricular
wall, reaching the endocardium, with or without trabecular
involvement. Subepicardial and mediomural lesions were de-
fined as lesions that affected less than two-thirds of the
ventricular wall, sparing the subendocardial portion. Ventricu-
lar aneurysm was defined as an external bulging or ex vacuo
hollow of a thinned ventricular region.
Histopathologic study. Full-thickness blocks of myocardium
were removed for histologic examination from each region of
the right and left ventricles and the septum, in a plan parallel
to the long axis of the ventricles. In five cases, a short-axis
cut of the whole heart at the mid third, including both
ventricles and septum, was also carried out (Fig. 1). Tissue
specimens were embedded in paraffin and routinely processed.
All myocardial sections (5 to 7 mm thick) were stained with
hematoxalin– eosin and azan techniques or hematoxylin–
phloxine–safranin O stain. The following morphologic lesions
were assessed and graded in the histologic specimens: 1)
myocardial atrophy and fatty replacement (severity [mild, mod-
erate, severe], transmural extent [subepicardial to full thick-
ness] and distribution [monofocal, multifocal, diffuse]); 2)
myocardial fibrosis (severity, extent, distribution and type [in-
terstitial or replacement]); 3) myocyte degeneration (atrophy,
contraction bands, acidophilic degeneration, vacuolization,
hypertrophy, and nuclear abnormalities) or necrosis (severity,
extent and distribution); 4) interstitial cell infiltrates (severity,
extent, distribution, predominant cell type [lymphocytes, giant
cells, neutrophils, eosinophils]) and predominant location [in-
terstitial, perivascular, perimyocyte, perinerve]); and 5) nerve
and intramural vessel abnormalities.
Statistical analysis. Results are expressed as mean value 6
SD. The unpaired Student t test was used to determine
significance between continuous variables. The chi-square or
Fisher test was used to assess the significance of differences
between subgroups. A value of p , 0.05 was considered
statistically significant.
Abbreviations and Acronyms
ARVC 5 arrhythmogenic right ventricular
cardiomyopathy/dysplasia
ECG 5 electrocardiogram, electrocardiographic
LV 5 left ventricular
RV 5 right ventricular
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Results
Clinical characteristics. The study group included 42 pa-
tients (27 male, 15 female). The age at time of death (or heart
transplantation) ranged from 9 to 65 years (mean age 29.6 6
18). Nine patients had a family history of premature sudden
death (age ,40 years), and eight had one or more relatives
affected by ARVC. Thirteen patients were competitive ath-
letes. In 12 patients, sudden death was not preceded by
warning symptoms and was the first and definitive manifesta-
tion of disease. The remaining 30 patients had experienced
arrhythmia-related symptoms, such as palpitations (n 5 30)
and syncopal episodes (n 5 11). Syncope was recurrent in six
patients and exercise related in seven.
A detailed clinical follow-up (from initial evaluation by a
cardiologist to death or heart transplantation) was available in
25 patients and ranged from a few months to 25 years (mean
6.35 years).
Nine patients had progressive functional limitation, evolv-
ing to overt, predominantly right heart failure in eight. In three
patients, the clinical course was complicated by embolic cere-
brovascular accidents that were fatal in one and led to persis-
tent hemiparesis in two.
Thirty-four patients (83%) died suddenly; the fatal event
was exercise related in 16 and occurred during a competitive
game in 9. Eight patients were taking antiarrhythmic drugs for
ventricular arrhythmias (previous aborted sudden death due to
ventricular fibrillation in one, sustained ventricular tachycardia
in three, nonsustained ventricular tachycardia in four) at the
time of sudden death: amiodarone in four patients (associated
with mexiletine in one), sotalol in three and propafenone in
one. Pharmacologic therapy had been “empiric” in seven and
guided by programmed ventricular stimulation in one. In four
patients, fatal cardiac arrest was due to recorded ventricular
fibrillation that was preceded by ventricular tachycardia in two.
Six hearts were from patients with heart failure refractory to
drug therapy who underwent heart transplantation (four pa-
tients) or died (two patients). Finally, one patient died of an
embolic stroke and another of cerebral malignancy.
A rest 12-lead ECG was available in 28 of 42 patients.
Inverted T waves on precordial leads were recorded in 27
patients and showed the following distribution: anteroseptal in
16 (leads V1 and V2 in 7, leads V1 to V3 or lead V4 in 9) (Fig.
2A) and anterolateral (leads V1 to V5 or lead V6) in 10 (with
extension to leads L1 and aVL in 4) (Fig. 3A). Other ECG
abnormalities included a low voltage QRS complex ,1 mV in
the peripheral leads in two patients, incomplete right bundle
branch block in two, “epsilon waves” on the right precordial
leads in two (Fig. 3A) and inverted T waves in the inferior
leads (II, III, aVF) in five (Fig. 2A and 3A).
During follow-up, five patients underwent pacemaker im-
plantation for sick sinus syndrome (three patients) or complete
atrioventricular block (two patients). Recurrent paroxysmal
atrial fibrillation was documented in two patients, both expe-
riencing cerebral embolism.
Ventricular arrhythmias were documented in 27 of 28
patients with available ECG tracings and included spontane-
ous sustained ventricular tachycardia in 9, nonsustained ven-
tricular tachycardia in 8 and isolated or coupled premature
ventricular beats in 10. Two patients had two different sus-
tained ventricular tachycardia morphologies. All types of sus-
tained ventricular tachycardia showed a left bundle branch
block pattern, with a superior axis in six patients, and inferior
axis in five (Fig. 3B). The ventricular tachycardia rate ranged
from 145 to 280 beats/min. Nonsustained ventricular tachycar-
dia ranged from 4 to 15 beats/min (left bundle branch block
pattern in five patients, multiform in three). Single and cou-
pled premature ventricular beats were the only documented
ventricular arrhythmia in 10 patients (monomorphic with left
bundle branch block pattern in 7, two or more morphologies
in 3).
Twenty-two patients underwent angiography or cross-
sectional echocardiography during life. The underlying cardio-
myopathy was not recognized in 7 patients (32%). In the other
15 patients, a diagnosis of RV cardiomyopathy (4 patients) or
biventricular cardiomyopathy (11 patients) was made on the
basis of global or regional ventricular dysfunction, or both.
Serial echocardiographic examinations (two or more) were
performed in 10 patients: progression of structural or func-
tional abnormalities, or both, were observed in eight patients
and consisted of worsening of RV function in all, associated
with the appearance (two patients) or worsening (five patients)
of LV abnormalities.
Pathologic findings. Gross morphologic features. There
were 38 necropsy study hearts and 4 transplantation hearts
(weight 164 to 780 g, mean 416 6 140). Global RV dilation was
Figure 1. Tissue specimen from a 25-year old man (group A) with a
family history of premature sudden death who died suddenly, without
warning symptoms. Short-axis macrohistologic section of the heart at
the mid-third, which includes the entire circumference of the RV free
wall, the interventricular septum and both anterior and posterior
paraseptal segments of the LV free wall. Note the transmural myocar-
dial atrophy, mostly consisting of fatty replacement with tiny interstitial
fibrosis, predominantly in the anterolateral region of the RV free wall.
The myocardium of the left ventricle and interventricular septum (only
partially visible in the section) is spared. Azan stain 33, reduced by
30%.
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seen in all 42 hearts and was mild in 3, moderate in 13 and
severe in 26. Aneurysmal dilations were identified in 20 hearts
at one or more of the following locations: RV inlet in 13, outlet
in 12 (Fig. 3C) and apex in 7. All hearts showed severe and
transmural RV muscle loss, with varying degrees of extent and
distribution. Atrophy of RV musculature was regional in five
cases (sparing inlet in two; apex, apex and inlet, and inlet and
outlet in one each) and widespread in the remaining 37. In 15
patients the loss of musculature, although transmural, was
homogeneously and completely replaced by fibrofatty tissue
and resulted in wall thickness preservation or only slight
thinning. In the remaining 27 hearts, the RV free wall dis-
closed a variable degree of thinning (thickness range 0.5 to
5 mm), with areas so thin as to appear completely devoid of
muscle at transillumination (Fig. 2C), and adjacent areas with
surviving subendocardial musculature and variable amounts of
fibrofatty replacements. Therefore, the RV wall shape ap-
peared irregularly deformed by thinning, scarring and bulging.
RV endocardial fibrosis was seen in 14 hearts (diffuse in 8,
patchy in 6), and 2 hearts exhibited diffuse epicardial thicken-
ing. Mural thrombosis in the RV cavity was found in one
instance.
LV involvement was diagnosed at gross examination in 17
hearts. The left ventricle was dilated in all cases (mildly in nine,
moderately in four, severely in four). In all hearts, changes in
LV musculature consisted of transmural or predominantly
subepicardial and mediomural fibrofatty replacement (Fig.
3E), which either affected diffusely both the septum and the
free wall (eight cases) or selectively involved some regions,
such as the posteroseptal or posterolateral wall, or both (six
cases), the anterolateral wall and apex (two cases) and the
septum and apex (one case). An anteroseptal LV aneurysm
was observed in one instance.
Histologic findings. Histologic examination disclosed severe
and transmural loss of RV myocardium in all heart specimens
(Fig. 1 to 3). According to gross inspection, microscopic lesions
diffusely affected the RV free wall in all but five cases. In 15
hearts the RV wall thickness was homogeneously preserved
and was almost completely filled with fatty tissue except for a
thin subendocardial layer and the trabeculae, which showed
surviving myocardium with degenerative changes, atrophy and
increased interstitial fibrosis (Fig. 1). The outer epicardial
border of wall musculature was often defined by a residual rim
of myocardial fibers.
In the other 27 hearts, there were areas of normal thickness
adjacent to areas of very severe wall thinning (#2 mm), which
was almost completely devoid of muscle fibers and extensively
Figure 2. Baseline ECG and tissue specimens from a 26-year-old
victim of sudden death (group B) with a history of syncope and
ventricular tachycardia with a left bundle branch block pattern.
Baseline 12-lead ECG with inverted T waves in inferior (L3, aVF) and
right precordial (V1, V2) leads (A). Panoramic histologic view of the
right ventricular free wall showing transmural fibrofatty replacement
(B [azan stain 33, reduced by 40%]). Panoramic histologic view of the
lateral LV free wall disclosing spots of fibrofatty substitution in
subepicardial and midmural myocardial areas (C [azan stain 33,
reduced by 43%]). At higher magnification, histologic examination of
the affected LV myocardium shows a mononuclear cell inflammatory
infiltrate surrounding dying myocytes (D [hematoxilin–eosin stain
3240, reduced by 46%]).
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replaced by a combination of fibrofatty tissue (Fig. 2B). The
epicardial boundary of wall musculature was no longer detect-
able. Surviving myocardial cells in affected areas disclosed
degenerative changes and atrophy.
LV involvement was diagnosed histologically in 32 cases.
LV fibrofatty substitution was transmural or predominantly
located in the subepicardial and mediomural wall layers in 28
cases (Fig. 2C and 3F); a diffuse increase in interstitial and
patchy replacement fibrosis was noted in the other 4 cases.
Both the septum and the LV free wall were affected in 23
hearts; 9 hearts disclosed selective free wall (8 hearts) or septal
(1 heart) involvement.
Multifocal inflammatory infiltrates were seen in 29 hearts
and affected both ventricles and the septum in 25, the RV
myocardium only in 3 and the LV myocardium only in 1.
Infiltrates consisted of scattered interstitial collections of
mononuclear cells, mainly located in the subendocardial region
close to necrotic or degenerative myocytes, or both (Fig. 2D).
In two cases, the inflammatory process had the features of a
focal giant cell myocarditis.
Correlation of results. Table 1 shows the comparison
between patients with and without LV involvement with
respect to a series of clinical and morphologic variables.
Patients were classified into three subgroups according to the
presence and severity of LV involvement: 1) group A 5 10
patients with isolated RV involvement (no LV lesions); 2)
group B 5 15 patients with histologic LV involvement only;
3) group C 5 17 patients with both histologic and macroscopic
LV involvement.
Patients in group C were significantly older than patients in
groups A and B (39 6 15 years vs. 20 6 8.8 and 25 6 9.7 years,
respectively), had longer clinical follow-up (9.3 6 7.3 years vs.
1.2 6 2.1 and 3.4 6 2.2 years, respectively), developed heart
failure significantly more often (47% vs. 0% and 0%, respec-
Figure 3. Baseline ECG and tissue specimens
from a 65-year old man (group C) with a long-
standing history of recurrent ventricular tachy-
cardia and progressive biventricular heart fail-
ure, who died of cerebral embolism. Baseline
12-lead ECG showing a low voltage QRS com-
plex, “epsilon waves” in leads V1 and V2 and
inverted T waves in inferior (L3 and aVF) and
precordial (V1 to V6) leads (A). Twelve-lead
ECG tracing of an episode of ventricular tachy-
cardia with left bundle branch block and inferior-
axis pattern (B). Gross view of the RV outflow
tract showing severe transmural loss of the RV
free wall and an infundibular parchment-like
aneurysm (C). Histologic view at high magnifi-
cation of surviving degenerated RV myocytes in
the setting of extensive fatty replacement and
tiny interstitial fibrosis (D [azan stain 375, re-
duced by 35%]). Gross (E) and histologic (F
[azan stain 33, reduced by 37%]) sections of the
anterior LV wall showing striking subepicardial
fatty infiltration and fibrosis.
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tively) and had an echocardiographic diagnosis of cardiomy-
opathy (100% vs. 45% and 0, respectively). Patients in groups
B and C had warning symptoms significantly more often (80%
and 87%, respectively, vs. 30%) and clinical ventricular ar-
rhythmias (73% and 82%, respectively, vs. 20%) than patients
in group A. In patients with LV involvement only, inverted T
waves on the lateral precordial leads (V5 and V6) were
recorded significantly more often in group C patients than
group B patients (71% vs. 10%). With regard to morphologic
variables, hearts from group C patients weighed more than
those from group A and B patients (500 6 150 g vs. 328 6 40
and 380 6 95 g, respectively); hearts from group B and C
patients had RV thinning (#2 mm) (87% and 71%, respec-
tively, vs. 20%) and inflammatory infiltrates (73% and 88%,
respectively vs. 30%) significantly more often than those from
group A patients. There was no statistically significant differ-
ence between the three groups with regard to family history for
sudden death or ARVC, athletic activity, occurrence of syn-
cope, right precordial T wave inversion, pacemaker implanta-
tion and presence of RV aneurysms.
Discussion
ARVC is a heart muscle disease that is characterized
pathologically by RV myocardial atrophy and fibrofatty re-
placement (1–5). Although initially considered to be strictly
confined to the right ventricle, there is growing clinical evi-
dence that over time, the left ventricle shares RV cardiomyo-
pathic changes (19–28). Long-term follow-up data from clini-
cal studies indicate that some patients with typical segmental
RV disease and a normal left ventricle at initial evaluation
Figure 3. Continued.
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progressively develop more diffuse RV involvement and LV
abnormalities with heart failure (21,22,24). This finding led the
World Health Organization/International Society and Federa-
tion of Cardiology Task Force to define ARVC as a disease of
the myocardium “characterized by progressive fibrofatty re-
placement of RV myocardium, initially with typical regional
and later global RV and some LV involvement” (29). Recog-
nition of patients with ARVC with biventricular involvement
may be difficult because they may resemble patients with
advanced dilated cardiomyopathy (22,24,27,28,30).
The present study reevaluated the anatomic and clinical
profile of ARVC, with special reference to disease progression
and LV involvement, by studying a large number of whole
hearts with distinctive RV myopathic changes and correlating
morphologic findings with clinical findings. The study revealed
that ARVC is a progressive heart muscle disease that may
present with the following clinicopathologic patterns: “silent”
myopathic abnormalities localized to the right ventricle in
asymptomatic victims of sudden death; “overt” disease char-
acterized by segmental or global RV structural changes, often
associated with only histologic evidence of LV involvement
and underlying symptomatic ventricular arrhythmias; “end-
stage” biventricular cardiomyopathy mimicking dilated cardio-
myopathy, which leads to progressive heart failure and may
require heart transplantation.
LV involvement. Previous reports (19–27) have suggested
that the left ventricle may be involved in ARVC, with global
or segmental disease, mostly located in the apical and
inferoposterior regions. In the present study, macroscopic
or histologic LV involvement, or both, was found in 76% of
the hearts analyzed, thus confirming that ARVC affects the
left ventricle in the majority of cases. LV changes usually
affected both the septum and LV free wall, either diffusely
or, more often, regionally, with a predeliction for the
posteroseptal and posterolateral areas. Lesions consisted of
large areas of transmural or subepicardial, or both, and
mediomural fibrofatty replacement of LV musculature. Pa-
tients with histologic LV changes disclosed patchy subepi-
cardial and mediomural fibroadipous substitution or a dif-
fuse increase in interstitial fibrosis. The wavefront of the
lesion appeared to extend from the outer to the inner layer
of the LV wall, similar to the pattern of involvement that has
been recognized in the RV free wall. It is noteworthy that
subepicardial myocardial lesions of the LV wall are rare in
other cardiac diseases. In fact, in a study of .5,500 hearts,
Shirani and Roberts (31), reported subepicardial myocardial
lesions in only 22, 6 of which showed the presence of
coronary artery disease.
Hearts with LV abnormalities weighed more and exhibited
RV as well as LV myocardial inflammatory infiltrates. Al-
though it is not clear whether inflammation in ARVC is a
primary event or a reaction to spontaneous necrosis (32),
inflammatory infiltrates are an histopathologic marker of an
ongoing myocardial damage that suggests a progressing
myocardial disease (28,32,33). The observation of giant cell
myocarditis in two patients does not permit any etiopatho-
genetic speculation because multinuclear giant cells have
been reported (34) to accompany various types of inflam-
matory response of unknown etiology and in diverse clinical
settings. In addition, LV involvement was age dependent,
was more common in patients with longstanding clinical
history and progressed during serial echocardiographic ex-
aminations in some patients. All these findings strongly
suggest that LV involvement is the result of ARVC progres-
sion. If the LV involvement is due to the same disease
process as that for the RV lesions or is mediated by different
or superimposed pathobiologic mechanisms, or both, re-
mains to be established. Apoptosis has recently been shown
(35–38) to be a mode of myocyte death in ARVC and might
provide a unifying explanation for progressive biventricular
myocardial loss.
The high prevalence and the distinctive “mural” distribu-
tion of LV changes are in agreement with the recent study of
Wichter et al. (39), in which MIBI scintigraphy provided
evidence for a structural or functional sympathetic denervation
in regions of LV myocardium adjacent to the right ventricle in
patients with ARVC. Because sympathetic nerve trunks course
in the subepicardium (40), they may be involved early in the
disease progression. It would be interesting to establish
whether apoptosis may involve ganglia and nerves as well.
The involvement of the conduction system in the present
study appeared as a late complication in the natural history of
the disease. Severe bradyarrhythmias, such as sinus sick syn-
Table 1. Clinical Characteristics and Morphologic Findings in
Patients With ARVC With or Without Left Ventricular Involvement
Group A
(n 5 10)
Group B
(n 5 15)
Group C
(n 5 17)
Age (yr) 20 6 8.8 25 6 9.7 39 6 15*†
Family history of
ARVC and/or SD
3 (30%) 8 (53%) 6 (35%)
Athletes 2 (20%) 7 (46%) 4 (23%)
Disease duration (yr) 1.2 6 2.1 3.4 6 2.2 9.3 6 7.3*†
Asymptomatic 7 (70%) 3 (20%)* 2 (13%)*
Syncope 3 (30%) 5 (33%) 3 (18%)
Inverted T waves
Right precordial leads
(V1–V4)
2/2 (100%) 11/12 (92%) 14/14 (100%)
Lateral leads (V5, V6) 0/2 1/12 (10%) 9/14 (71%)†
Ventricular arrhythmias 2 (20%) 11 (73%)* 14 (82%)*
“Normal” echo 2/2 (100%) 5/9 (55%) 0/11*†
PM implantation 0 0 5 (29%)
Heart failure 0 0 8 (47%)*†
Heart weight (g) 328 6 40 380 6 95 500 6 150*†
Significant RV wall
thinning (#2 mm)
2 (20%) 13 (87%)* 12 (71%)*
RV aneurysms 3 (30%) 10 (66%) 7 (41%)
Inflammatory infiltrates 3 (30%) 11 (73%)* 15 (88%)*
*p , 0.05 versus group A. †p , 0.05 versus group B. Data presented are
mean value 6 SD or number (%) of patients. ARVC 5 arrhythmogenic right
ventricular cardiomyopathy/dysplasia; echo 5 echocardiographic; Group A 5
isolated right ventricular (RV) involvement; Group B 5 histologic left ventric-
ular involvement; Group C 5 gross left ventricular involvement; PM 5 pace-
maker; SD 5 sudden death.
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drome and complete atrioventricular block requiring pace-
maker implantation, occurred only in older patients with
severe biventricular cardiomyopathy.
Because the extension of T wave inversion in the ECG
lateral leads (V5, V6, L1, aVL) was unique to patients with
ARVC with advanced LV changes, it appears to be an
important clinical marker for significant LV involvement.
Isolated RV involvement. In the current study, 10 patients
showed isolated RV changes. They were younger and more
often died suddenly without having experienced warning symp-
toms than patients with coexistent LV abnormalities. Hearts
with isolated RV changes weighed less, had less severe RV wall
thinning and infrequently showed ventricular myocardial in-
flammatory infiltrates. There were no statistically significant
differences with regard to familiarity for sudden death or
ARVC, athletic activity and right precordial T wave inversion.
All these data demonstrate that there is a subset of patients
with ARVC who die suddenly at an early stage of the disease
(3,4,41).
Fatal outcome. The natural history of ARVC is a function
of both the electrical instability of dystrophic myocardium,
which can precipitate sudden “arrhythmic” cardiac arrest any
time during the disease course, and the progressive myocardial
loss that results in ventricular dysfunction and heart failure.
Sudden death accounted for 75% of the fatal outcomes in
the present series of ARVC, and although it occurred at every
stage of the disease, it was more common in adolescents and
young adults. The mechanism of sudden cardiac arrest is
thought to be arrhythmic because ventricular tachycardia or
fibrillation has been previously documented both in patients
with ARVC who died suddenly and in those who were
successfully resuscitated (1,3,4,42–45). In the present series,
the ECG, when available, always showed ventricular arrhyth-
mias, which ranged from individual premature ventricular
beats to sustained ventricular tachycardia. Ventricular tachy-
cardia degenerating into fibrillation was documented in five
patients.
Eight patients died suddenly while taking antiarrhythmic
drugs to treat ventricular arrhythmias. However, pharmaco-
logic therapy was “empiric” in seven patients and guided by
programmed ventricular stimulation in one. Although data on
the efficacy on antiarrhythmic therapy in ARVC cannot be
derived from the present series, these results warn that empiric
pharmacologic treatment of life-threatening ventricular ar-
rhythmias in ARVC, even with class III antiarrhythmic drugs,
may be unsuccessful.
Sudden death was frequently exercise related and occurred
in young competitive athletes during sporting activities. This
finding is in agreement with a previous prospective study (4) on
fatal events in young people in the Veneto Region of Italy, in
which ARVC was the most frequent cause of sport-related
sudden cardiac arrest, being responsible for nearly 30% of
death in young competitive athletes.
Heart failure has been reported (21,22,24) to complicate
the follow-up of ARVC in up to 20% of cases. Our study
confirms that heart failure is an important cause of fatal
outcome or heart transplantation in long-standing disease.
Heart failure appears to reflect the progression of the myocar-
dial disease because it occurred in older patients with a longer
clinical history and pathologic evidence of more severe cardi-
omegaly and gross LV involvement. Clinical follow-up showed
that a progressive worsening of functional limitation preceded
overt heart failure, and, when available, serial echocardio-
graphic examinations revealed progressive impairment of RV
function with new appearance or worsening of LV abnormal-
ities.
Potential study limitations. In the present study, patients
with ARVC came from different European countries where
the clinicopathologic manifestation of the disease may vary
according to the heterogeneous genetic background; therefore,
the different source of patients may account for a selection bias
in the anatomic and clinical profile of the disease.
ARVC usually has a more benign clinical course than that
reported in the present study, which addressed only patients
who died and patients undergoing heart transplantation, with
the most striking morphologic and clinical features of the
disease. Nevertheless, the primary aim of the present study was
to redefine the anatomic and clinical profile of ARVC, with
special reference to LV involvement and progression, in
patients with the disease proved at autopsy.
The present study did not address atrial myocardial pathol-
ogy, although fatty infiltration even of atrial myocardium has
been occasionally observed in ARVC and may account for
sinus node dysfunction and other atrial arrhythmias.
Conclusions. ARVC is a progressive heart muscle disease
that may present clinically different stages. The tendency to
progress and to involve the left ventricle accounts for a wide
range of clinical and pathologic manifestations. The spectrum
ranges from concealed RV myopathic changes detected at
autopsy in previously asymptomatic young victims of sudden
death to biventricular cardiomyopathy with severe pump failure.
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